| Identification of cell cycle–regulated genes periodically expressed in U2OS cells and their regulation by FOXM1 and E2F transcription factors GD Grant, L Brooks 3rd, X Zhang, JM Mahoney, V Martyanov, TA Wood, ... Molecular biology of the cell 24 (23), 3634-3650, 2013 | 194 | 2013 |
| Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis M Hinchcliff, CC Huang, TA Wood, JM Mahoney, V Martyanov, ... Journal of Investigative Dermatology 133 (8), 1979-1989, 2013 | 188 | 2013 |
| Systems level analysis of systemic sclerosis shows a network of immune and profibrotic pathways connected with genetic polymorphisms JM Mahoney, J Taroni, V Martyanov, TA Wood, CS Greene, PA Pioli, ... PLoS computational biology 11 (1), e1004005, 2015 | 145 | 2015 |
| Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double‐blind, placebo‐controlled, pilot trial JK Gordon, V Martyanov, JM Franks, EJ Bernstein, J Szymonifka, C Magro, ... Arthritis & rheumatology 70 (2), 308-316, 2018 | 124 | 2018 |
| Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis EF Chakravarty, V Martyanov, D Fiorentino, TA Wood, DJ Haddon, ... Arthritis research & therapy 17, 1-14, 2015 | 124 | 2015 |
| A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis JN Taroni, CS Greene, V Martyanov, TA Wood, RB Christmann, ... Genome medicine 9, 1-24, 2017 | 106 | 2017 |
| Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial JK Gordon, V Martyanov, C Magro, HF Wildman, TA Wood, WT Huang, ... Arthritis research & therapy 17, 1-14, 2015 | 102 | 2015 |
| Myeloid cells that impair immunotherapy are restored in melanomas with acquired resistance to BRAF inhibitors SM Steinberg, TB Shabaneh, P Zhang, V Martyanov, Z Li, BT Malik, ... Cancer research 77 (7), 1599-1610, 2017 | 92 | 2017 |
| Safety and efficacy of lenabasum in a phase II, randomized, placebo‐controlled trial in adults with systemic sclerosis R Spiera, L Hummers, L Chung, TM Frech, R Domsic, V Hsu, DE Furst, ... Arthritis & Rheumatology 72 (8), 1350-1360, 2020 | 87 | 2020 |
| Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease V Martyanov, GHJ Kim, W Hayes, S Du, BJ Ganguly, O Sy, SK Lee, ... PLoS One 12 (11), e0187580, 2017 | 72 | 2017 |
| Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures JN Taroni, V Martyanov, CC Huang, JM Mahoney, I Hirano, B Shetuni, ... Arthritis Research & Therapy 17, 1-14, 2015 | 71 | 2015 |
| A machine learning classifier for assigning individual patients with systemic sclerosis to intrinsic molecular subsets JM Franks, V Martyanov, G Cai, Y Wang, Z Li, TA Wood, ML Whitfield Arthritis & rheumatology 71 (10), 1701-1710, 2019 | 66 | 2019 |
| Profibrotic activation of human macrophages in systemic sclerosis R Bhandari, MS Ball, V Martyanov, D Popovich, E Schaafsma, S Han, ... Arthritis & Rheumatology 72 (7), 1160-1169, 2020 | 60 | 2020 |
| Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic … S Lenna, AG Farina, V Martyanov, RB Christmann, TA Wood, HW Farber, ... Arthritis & Rheumatism 65 (5), 1357-1366, 2013 | 60 | 2013 |
| Senescence signature in skin biopsies from systemic sclerosis patients treated with senolytic therapy: potential predictor of clinical response? V Martyanov, ML Whitfield, J Varga Arthritis & rheumatology (Hoboken, NJ) 71 (10), 1766, 2019 | 45 | 2019 |
| Live-cell monitoring of periodic gene expression in synchronous human cells identifies Forkhead genes involved in cell cycle control GD Grant, J Gamsby, V Martyanov, L Brooks 3rd, LK George, ... Molecular biology of the cell 23 (16), 3079-3093, 2012 | 41 | 2012 |
| The Tsk2/+ mouse fibrotic phenotype is due to a gain-of-function mutation in the PIIINP segment of the Col3a1 gene KB Long, Z Li, CM Burgwin, SG Choe, V Martyanov, S Sassi-Gaha, ... Journal of Investigative Dermatology 135 (3), 718-727, 2015 | 38 | 2015 |
| Machine learning predicts stem cell transplant response in severe scleroderma JM Franks, V Martyanov, Y Wang, TA Wood, A Pinckney, LJ Crofford, ... Annals of the rheumatic diseases 79 (12), 1608-1615, 2020 | 34 | 2020 |
| Molecular stratification and precision medicine in systemic sclerosis from genomic and proteomic data V Martyanov, ML Whitfield Current opinion in rheumatology 28 (1), 83-88, 2016 | 32 | 2016 |
| A functional genomic meta-analysis of clinical trials in systemic sclerosis: toward precision medicine and combination therapy JN Taroni, V Martyanov, JM Mahoney, ML Whitfield Journal of Investigative Dermatology 137 (5), 1033-1041, 2017 | 31 | 2017 |
